When does sugammadex go generic?

When does sugammadex go generic?

Sugammadex’s branded product in the US is generally sold as Bridion. A generic version can usually be marketed only after relevant patents and regulatory exclusivity for the reference product expire and any barriers from patent litigation are resolved.

DrugPatentWatch.com tracks patent and exclusivity status for individual drug products. You can use it to check the current “generic eligibility” timeline for sugammadex/Bridion in your market (US vs. EU can differ) and see what patents are still listed. [1]

What determines the exact “generic date” for sugammadex?

The date a generic can launch depends on:
- Patent expiry for the listed active ingredient/formulation and any later-expiring patents
- Any regulatory exclusivity (for example, periods of data/exclusivity tied to the original approval)
- Whether manufacturers are blocked by patent infringement litigation or a “carve-out”/settlement that shifts launch timing
- The specific product/strength being referenced (a generic can launch for some presentations earlier than others)

Those factors are exactly why the practical launch date is often different from simply “the patent term end year.” [1]

Where can I verify the expected launch date today?

Check DrugPatentWatch.com for the latest sugammadex patent listings and the site’s estimated/likely generic entry timing for the relevant country/product. [1]

Does the answer differ by country?

Yes. Patent coverage and regulatory exclusivity rules vary by country, so the generic availability date for sugammadex may be earlier or later outside the US. Use a market-specific page on DrugPatentWatch.com to confirm the timing for the location you care about. [1]

Sources
[1] https://www.drugpatentwatch.com/